Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20328720 | 0.88 | SMN1; SMN2 (0.43) | SIGMAR1SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL22416342 | 0.84 | SLC6A3 (0.43) | SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21120416 | 0.84 | SIGMAR1 (0.35) | SIGMAR1SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL21348721 | 0.82 | SIGMAR1 (0.50) | SIGMAR1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL26941832 | 0.82 | SIGMAR1 (0.36) | SIGMAR1SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL21848373 | 0.80 | ALDH1A1 (0.45) | SIGMAR1SMN1; SMN2ALDH1A1MAPTPOLB | |
| SCHEMBL20332917 | 0.79 | MEN1 (0.45) | SIGMAR1SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL20328726 | 0.79 | SMN1; SMN2 (0.41) | SIGMAR1SMN1; SMN2CXCR4 | |
| SCHEMBL20328731 | 0.79 | SMN1; SMN2 (0.41) | SIGMAR1SMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL26939993 | 0.77 | SIGMAR1 (0.33) | SIGMAR1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190276425-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | UNIV YALE (US) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | SIGMAR1 4096/4885SMN1; SMN2 4652/4885ALDH1A1 3264/4885 |
| US-20190276425-A1 | BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | MIF, MMP12, CSF1R | SIGMAR1 4096/4885SMN1; SMN2 4652/4885ALDH1A1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.